Trial 3C-09-2

A Multi-Center, Open-Label, Randomized, Phase II Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Colorectal Cancer with Metastatic or Locally Advanced Disease.

Type: Cancer Therapy
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Heinz Josef Lenz, M.D.
Other Trial Staff: Ramona Lujan, R.N., Carol Jones, R.N., Taison Tran, D.M., Khatchik Karakozian, D.M., Catherine Ticong, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.